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Sllmmary 
Anticardiolipin antibodies (aCL) derived from the sen of individuals exhibiting the antiphospholipid 
syndrome (APS) directly bind to 3z-glycoprotein  I (3z-GPI), which is adsorbed to an oxidized 
polystyrene surface. Oxygen atoms were introduced on a polystyrene surface by irradiation with 
dectron or 'y-ray radiation. X-ray photoelectron spectroscopy revealed the irradiated surfaces were 
oxidized to generate C- O and C = O moieties, aCL derived from either APS patients or (NZW 
x  BXSB)F1 mice bound to ~z-GPI coated on the irradiated plates, depending on the radiation 
dose.  Antibody binding to  3z-GPI  on the irradiated  plates  was  competitively inhibited by 
simultaneous  addition of cardiolipin (CL)-coated latex beads mixed together with 13z-GPI but 
were unaffected by addition of excess 132-GPI, CL micelles, or CL-coated htex beads alone. There 
was a high correlation between binding values of aCL in sera from 40 APS patients  obtained 
by the anti-3z-GPI enzyme-linked immunosorbent assay (ELISA) using the irradiated plates and 
those by the 32-GPI-dependent  aCL ELISA. Therefore,  aCL have specificity for an epitope on 
3z-GPI. This epitope is expressed by a conformational change occurring when 3z-GPI interacts 
with an oxygen-substituted solid phase surface. 
ntiphospholipid  antibodies (APA)  1 are a family of closely 
related immunoglobulins that react with anionic phos- 
pholipids.  Racent studies  would suggest  these antibodies 
recognize complexes of anionic phospholipids  and a variety 
of plasma  proteins,  including 13z-glycoprotein I (~z-GPI), 
prothrombin, and proteins  C  and S (1-7).  Anticardiolipin 
antibodies  (aCL) and lupus anticoagulants  are members of 
the APA family. Both aCL and lupus anticoagulants are found 
in sera of patients with SLE or related connective tissue dis- 
eases (8-14).  The term, antiphospholipid  syndrome (APS), 
has been proposed to explain the association of APA and a 
variety of clinical features, including arterial and venous throm- 
boembolic events, recurrent spontaneous abortion or intrau- 
terine fetal death, thrombocytopenia, and various neurologic 
defects (10, 11). 
t Abbreviations used in this paper: aCL, anticardiolipin antibodies; APA, 
antiphospholipid antibodies; APS, antiphospholipid syndrome; ~2-GPI, 
~z-glycoprotein I;  (EL, cardiolipin; HRP,  horseradish peroxide; PL, 
phospholipid; XPS, x-ray photoelectron spectroscopy. 
aCL are usually detected by either ILIA or ELISA, using 
cardiolipin ((EL) as a solid phase antigen (8, 9). In recent years, 
several groups (1-5) have shown that a 50-kD serum cofactor 
is required for aCL found in SLE patients to bind to plastic 
plates coated with CL. The cofactor has been identified as 
~2-GPI by detecting an NHz-terminal amino acid sequence 
of the purified protein (1, 5) and by cDNA cloning and se- 
quencing (15). Further, the cofactor activity of :/z-GPI that 
provides the aCL binding in aCL ELISA was shown to be 
retained by recombinant ~2-GPI produced in an expression 
system utilizing baculovirus/Spodopterafrugiperda cells (16). 
We and others have also shown that such types of aCL are 
distinguished from aCL found in patients with infectious dis- 
orders, such as syphilis, malaria,  hepatitis  A, tuberculosis, 
or infectious mononucleosis,  which react with solid phase 
and fluid phase CL in the absence of 132-GPI (5,  17). 
Thus, aCL found in SLE patients are not simply directed 
to the CL structure but the aCL binding requires the pres- 
ence  of fl2-GPI. However,  the  epitopic  site(s) that  aCL 
recognizes  has not been immunologically defined.  Three 
different hypotheses have been proposed to explain the aCL, 
CL, and flz-GPI interactions:  (a) the fl2-GPI-CL  complex 
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is the actual target antigen for aCL but the epitope is cryptic 
in the absence of CL (5); and (c) the actual epitope for aCL 
appears  on the native structure of 32-GH (2,  18,  19). 
To distinguish among these possibilities,  we used oxygen 
introduced onto polystyrene  surfaces by irradiation with elec- 
tron or 3c-ray radiation. The introduction of polar groups 
to a polystyrene surface is accomplished by covalent coupling 
of oxygen atoms to polystyrene, using high energy irradia- 
tion with electron, "y-ray, or ultraviolet radiation or plasma 
treatment (20-22). aCL derived from either APS patients or 
(NZW  x  BXSB)F1 mice, an animal model of human APS 
(23),  bound to 32-GPI coated on the irradiated plates,  de- 
pending on the radiation dose. aCL binding to/32-GPI ad- 
sorbed to oxygen-substituted solid phase was correlated well 
with  that  of fl2-GPI  complexed to  solid phase  CL.  Our 
results  strongly suggest  that  aCL from APS  recognize a 
modified form of 32-GPI created by adsorption of the pro- 
tein to a polyoxygenated surface, but not CL or native form 
of fl2-GPI,  or an epitope structurally defined by both CL 
and/32-GPI. 
Materials and Methods 
Reagents.  CL (from bovine heart) was obtained from Sigma 
Chemical Co. (St. Louis, MO); BSA (ultrapure grade) from Life 
Technologies  Inc. (Grand  Island,  NY); horseradish  peroxidase  (HRP) 
from Toyobo Co. (Osaka, Japan). All other chemicals were from 
commercial sources and of reagent grade. 
Sera.  aCL-positive  sera were obtained from SLE patients who 
fulfilled the revised criteria of American Rheumatism Association 
in  1982. All patients exhibited significantly high levels of/32- 
GPI-dependent aCL as compared  with healthy subjects, and showed 
one or more of symptoms of APS, i.e., thromboembolic complica- 
tions (venous and/or arterial), recurrent spontaneous abortion, and 
thrombocytopenia (10, 11). 
Micwtiter Plates.  96-well  microtiter plates (plain polystyrene; 
MS-3496F) were obtained from Sumitomo Bakelite Co.,  Ltd. 
(Tokyo,  Japan). The plates were irradiated with dectron beam (25 
or 50 kGy) or with cobalt-60",/-ray  (6.3, 25, or 100 kGy) radiation 
under an ambient oxygen atmosphere. 
Preparation of CLcoated Latex 13eadx  Polystyrene  divinylbenzene 
beads of 6.4 + 2.0 #m diameter in the form of a 10% uniparticu- 
late dispersion in colloidal silica were obtained from Seradyn Inc. 
(Incllanapolis, IN). Beads were first washed to remove  colloidal  silica 
and lyophilized as described (24). 200 mg of the decolloidal silica 
beads was dispersed in 2.0 ral of heroine/ethanol (1:1) and added 
to an ethanolic solution of CL (250 #g/100 #1). The beads were 
then briefly dispersed in a bath-sonicator and dried under a stream 
of nitrogen. The dry beads were redispersed in 3.0 ml of distilled 
water and washed three times by centrifugation at 300 g for 3 min. 
The amount of CL coated on the beads was measured according 
to the method of Bartlett (25). 
Preparation of ~rGPI.  ~rGPI  was  purified from  normal 
human sera  by sequential  CL-a~nity  and ion exchange column and 
protein A-Sepharose  column chromatography  as described (12). Fur- 
ther, the preparation was delipidated by washing three times with 
butanol. The preparation resulted in a polymorphic 50-kD band 
detected by SDS-PAGE. Finally, an NH2-terminal amino add se- 
quence of the preparations was determined by Edman degradation 
with a vapor phase protein sequencer (Modal PSQ-1; Shimadzu 
Seisakusho, Kyoto, Japan). The  NHrterminal  sequence data 
demonstrated that the preparation contained homogeneous 82- 
GPI. Analysis of the/~2-GPI preparation also revealed that the 
preparation did not contain any significant phospholipid contami- 
nation (25). 
mAbs.  A murine mAb, WB-CAL-I (IgG2a, K), was derived 
from (NZW  x  BXSB)FI (WB F1) male mice, an animal model 
of human APS (23). Another mAb directed to 32-GPI, Col-18 
(IgG1, K), was developed from BALB/c female mice immunized 
with Freund's adjuvant-emulsified human  fl2-GPl. These anti- 
bodies were produced as ascites and were purified sequentially by 
ammonium sulfate precipitation and protein A-Sepharose affinity 
chromatography. 
$u~ce Analyses.  X-ray  photoelectron spectroscopy (XPS) of 
polystyrene  surface  was analyzed  with an ESCA spectrometer {JPS- 
9000MC; JEOL Ltd., Tokyo, Japan) utilizing Mgkala radiation 
at 1,253.6 eV. Survey scan spectra (0-1,000 eV) were preliminarily 
performed for surface  demental analyses  and then Cls spectra were 
taken at the analyzer's pass energy, 10 eV (resolution: 0.9 eV at 
Ag 3d 5/2 peak). The binding energy was calibrated  to C-C binding 
energy (285.0 eV) of Cls spectra. 
B2-GPI-dependent aCL ELISA.  32-GPI-dependent  aCL ELISA 
was performed as previously  described (5) with slight modification. 
CL in ethanol (2.5 #g/50 #1 per well) was coated on the surface 
of  wells of  96-well microtiter plates (plain polystyrene)  by evapora- 
tion under nitrogen. The Cbcoated wells were incubated with 50 
#1 of 10 mM Hepes, 150 mM NaC1 (pH 7.4) containing 0.3% 
BSA (Hepes-BSA) for 1 h at 37~  and were washed three times 
with 200 #1 of PBS (pH 7.4) containing 0.05% Tween 20 (PBS- 
Tween). The wells were incubated with 50 #1 of Hepes-BSA con- 
taining ~2-GH (30 #g/m1) for 30 rain at room temperature and 
were washed in the same manner. Then, the wells were incubated 
with 50 #1 of diluted samples at room temperature for 30 rain. 
After washing with PBS-Tween, the wells were incubated with 100 
#1of HRP-labeled murine mAb against human IgG (G-02; Yamasa 
Corp., Choshi, Japan) or goat anti-mouse IgG for 30 rain at room 
temperature. The wells were again washed and incubated with 100 
#1 of 0.3 raM tetramethylbendizine solution containing 0.003% 
of H202. After 10 rain of incubation, the reaction was terminated 
by adding 100 #1 of 2 N H2SO4 and the OD was measured at 450 
am. 
Anti-~2-GPl ELISA.  Antibodies  directed to ~2-GPI were also 
assayed by ELISA. Wells of 96-well microtiter plates (plain or ir- 
radiated polystyrene plates) were coated with 50 #1 of 32-GPI (10 
#g/ml dissolved  in 10 mM Hepes, 150 mM NaC1, pH 7.4, (Hepes 
buffer), for 16-20 h at 4~  After the incubation, the 32-GPI- 
coated wells were washed three times with 200 #1 of PBS-Tween, 
and then were incubated with 200 #1 of Hepes buffer containing 
3% gelatin (0143-01; Difcu Laboratories, Detroit, MI) for 1 h at 
room temperature. After washing in the same manner, the wells 
were incubated with 50 #1 of d/luted samples for 1 h at room tem- 
perature. The wells were again washed and incubated with 100 
#1 of HRP-labeled murine anti-hnman  IgG or goat anti-mouse 
IgG for 1 h at room temperature. The color was developed and 
the OD was measured as described above. 
Results 
Specificity of Antibodies Defined by ~2-GPI-dependent aCL 
ELISA and anti-fl~-GPI ELISA.  Table 1 presents the data 
for SLE-1, WB-CAL-1, and Col-18 binding to surfaces coated 
with either CL or [32-GPI. SLE-1 serum was obtained from 
a patient with APS. WB-CAL-1 is a monodonal autoanti- 
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Binding to CL coated on plates 
Antibody  -B2-GPI  +B2-GPI (15/~g/ml)  Binding to ~2-GPI on plates 
SLE-1  0.023  1.072  0.043 
WB-CAL-1  0.021  1.159  0.033 
Cof-18  0.030  1.103  1.213 
50 #I of SLE-1 serum (200-fold dilution), WB-CAL-1 antibody (0.5/~g/ml), or Cof-18 antibody (0,5/~g/ml) were added to the wells. These values 
indicate OD at 450 nm detected by the/$z-GPI-dependent aCL ELISA and by the anti-Bz-GPI ELISA using plain polystyrene plates. 
body derived from WB F1 mice. Cof-18 is a murine mAb 
against ~2-GPI. To avoid the influence of endogenous 82- 
GPI, these mAbs were purified and SLE-1 serum was finally 
diluted 200-fold. The antibodies SLE-1 and WB-CAL-1 bound 
to CL-coated plates (plain polystyrene) when the plates were 
previously or simultaneously  incubated  with ~2-GPI, but 
not to ~2-GPI-coated plates directly. The antibody Cof-18 
bound to either B2-GPI-coated plates directly or CL-coated 
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Figure  1.  Analyses of molecular chains on the polystyrene surfaces. The 
values indicate atomic mol% of molecular chains on the polystyrene sur- 
faces calculated from Cls spectra and binding  energy (in parentheses). The 
XPS was analyzed as described in Materials and Methods. 
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plates when the plates were previously incubated with ~2- 
GPI. These results confirm that SLE-1 and WB-CAL-1 an- 
tibodies recognize the complex of/~2-GPI and CL, and that 
Cof-18 antibody is directed to Bz-GPI. 
Introduction of Oxygen Atoms  onto the Polystyrene Surface. 
XPS data revealed  that the plain polystyrene surface was com- 
posed entirely of aliphatic carbons (Fig. 1). The Cls peak at 
285.0 eV was exhibited a full width at half-maximum of 1.29 
eV. No nitrogen and a trace of oxygen (1.3 atomic mo1%) 
was detected on the surface. Once polystyrene plates were 
irradiated with electron (50 kGy) or "y-ray  (100 kGy), an in- 
crease of intensity in Ols peak and an apparent shoulder on 
the high binding energy side of the Cls peak were observed. 
The increased full width at half-maximum for the Cls spectra 
was accompanied by an increase in the shoulder on the Cls 
peak (1.37 and 1.43 eV, respectively). The Ganssian/Lorent- 
zian (80:20) curve fitting was used for analyses. A peak at 
286.4 eV corresponding to single bond of carbon to oxygen 
(C-O, 8.2 atomic tool%) appeared  in the high binding energy 
Cls shoulders of the electron (50 kGy)-irradiated plates, and 
the shoulder of "y-ray (100 kGy)-irradiated plates were fur- 
ther resolved into two peaks, representing a C-O bond (5.3 
atomic tool%) at 286.0 eV and a double bond to oxygen 
(C=O, 3.9 atomic tool%) at 287.1 eV. These results indicate 
that the irradiation  with electron or "y-ray radiation  could 
covalently introduce oxygen atoms onto the surfaces of  poly- 
styrene plates caused by producing oxidized carbons (alcohol, 
ether,  and/or carbonyl groups). 
aCL Binding to ~z-GPI Coated on the Irradiated Polystyrene 
Su~ce.  We initially examined antibody binding to ~2-GPI 
coated on polystyrene surfaces irradiated under the various 
dose conditions of electron or "y-ray. Increased binding of 
SLE-1 and WB-CAL-1 antibodies to the irradiated plates de- 
pending on the radiation  dose are shown in Fig. 2, A  and 
B. The maximal binding of either SLE-1 or WB-CAL-1 an- 
tibodies to ~/2-GPI-coated plates irradiated with 100 kGy of 
"y-ray  radiation showed an OD of 1.161 and 1.087, and their 
control binding to ~2-GPI coated on nontreated plates gave 
an OD of 0.070 and 0.043, respectively. In contrast, Cof-18 
antibody appreciably bound to nontreated plates (an OD of 
0.917) and a slightly increased  binding was observed  (Fig. 2 C). 
To study the molecular basis of the specificity of aCL, a 
competitive anti-~/2-GPI ELISA using the irradiated polysty- ].2  (A) SLE-1 
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Figure 2.  Antibody binding to/3z-GPI coated on the irradiated poly- 
styrene plates. SLE-1 serum (200-fold dilution), WB-CAD1 antibody (0.5 
/~g/ml), or Cof-18 antibody (0.5 ~g/ml) was incubated in/5z-GPI-coated 
wells of which polystyrene plates were previously irradiated or not. Each 
bar represents  the mean and SD (n  =  5). 
rene plates with 100 kGy of 3,-ray radiation was carried out. 
The ELISA was assayed under the simultaneous addition of 
SLE-1, WB-CAL-1, or Cof-18 antibody with various inhib- 
itors. As shown in Fig. 3, binding of either SLE-1 or WB- 
CAL-1 antibody in the ELISA was competitively inhibited 
by the addition of CL-coated latex beads at varying CL con- 
centration from 0 to 4.0 #g/m[ mixed together with 10/,Lg/ml 
of/32-GPI. 50%  inhibition of the SLE-1 and WB-CAL-1 
binding was obtained by addition of the/3z-GPI-CL com- 
plex composed of 0.66 and 0.71 #g/m1 of CL, respectively 
There was no or slight inhibitory effect with either high excess 
of CL micelles (500/zg/ml) or/32-GPI (500/~g/ml) alone. 
In contrast, the binding of Cof-18 antibody in the ELISA 
was inhibited by the addition of/32-GPI (0-500/zg/ml) in 
a dose-dependent manner but was not inhibited by the addi- 
tion of 500/~g/ml CL miceUes. Similar phenomena were ob- 
served in the ELISA system using the/32-GPI-coated plates 
that were previously irradiated with 50-kGy electron radiation. 
Significance of Anti-:grGPI Antibodies Detected by Using :92- 
GPI Coated on the Irradiated Polystyrene Plates.  To evaluate 
the prevalence of anti-/3z-GPI antibodies that recognize the 
protein associated with the oxidized surface, 40 sera of APS 
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Figure 4.  Correlation between antibody values in sen from APS pa- 
tients obtained by the anti-/J~-GPl ELISA using the irradiated plates with 
100 kGy of "y-ray radiation and those by the/~2-GPl-dependent aCL 
ELISA. 
patients associated with both of SLE and APS were tested 
in the two ELISA systems. As shown in Fig. 4, there was 
a high correlation (r = 0.89, p < 0.01) between binding values 
(OD) of aCL in sera from 40 APS patients detected by the 
anti-B2-GPI ELISA using the irradiated plates with 100 kGy 
of y-ray radiation and those by the/32-GPI-dependent aCL 
ELISA. 
Discussion 
APA such as aCL have been frequently detected in sera 
from patients with SLE or related connective tissue disorders 
(8-14).  Recent studies (1-5)  have shown that/3z-GPI is in- 
volved in aCL binding to solid phase CL but aCL do not 
recognize the CL structure directly. In the present study, we 
further characterized the binding properties of aCL by ELISA 
using irradiated polystyrene plates. 
It has been demonstrated that/32-GPI can bind to a va- 
riety of negatively charged molecules, including phospho- 
lipids (PL) (5) and heparin (26), whereas the aCL from APS 
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Figure 3.  A simultaneous  competitive  in- 
hibition  assay  for  antibody  binding  in  ELISA 
using  ~2-GPI coated  on the  irradiated  plates 
with  100  kGy  of  ?-ray  radiation.  SLE-I  stream 
(200-fold  dilution),  WB-CALI antibody  (0.5 
~tglml),  or  Cof-18  antibody  (0.5  ~g/ml)  was 
incubated  into  ~2-GPl-coated  wells  of the 
plates.  ~2-GPI (0~  O), CL mi- 
celles (00500  /zg/rul, I-'l), CL-coated  latez 
beads  (0--4.0  #g/mI  ofCL, I),  or  CLcoated 
late~  beads  (0--4.0/~g/ml  of  CL, 0) mixed 
together  with  10  ~g/ml  of flz-GPI  was 
added to the wells as an inhibitor. Antibody 
binding  was  determined  as  described  in 
Materials and Methods. 
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coated on polystyrene plates (1, 3-5), or polyacrylamide gels 
in which liposomes composed of CL or phosphatidylserine 
were entrapped (1, 5,  27). 
The present data show that the aCL bound directly to ~2- 
GPI coated on an irradiated polystyrene surface in the ab- 
sence of CL. The XPS analyses showed that a significant 
amount of oxygen was covahntly introduced onto the sur- 
face of the irradiated plates but any other atomic composi- 
tions were not changed. The extent of aCL binding was de- 
pendent upon the radiation dose applied to the surface (Fig. 
2). The maximal binding of either SLE-1 or WB-CAL-1 an- 
tibody was observed with 100 kGy of "y-ray radiation and 
their bindings were 16.6- and 25.3-fold greater as compared 
with controls, respectively. Moreover, the aCL binding was 
inhibited by simultaneous addition of CL-coated latex beads 
mixed together with/32-GPI but not by/~2-GPI, CL mi- 
celles, or CL-coated latex beads  alone (Fig.  3). 
Arvicux et al.  (18) have shown that antibody binding 
directed to/~2-GPI coated on the polystyrene plates was in- 
hibited by prior incubation with liposomes composed of nega- 
tivdy charged PL (CL or phosphatidylserine) and cholesterol, 
depending on the PL dose. We have further confirmed evi- 
dence that inhibitory effect on antibody binding to Bz-GPI 
coated on the irradiated polystyrene plates with 100 kGy of 
~/-ray radiation was provided by prior incubation with a mix- 
ture  of/3z-GPI  and  CL  micelles  but  was  not  with  CL 
miceUes or 32-GPI alone (our unpublished data).  This evi- 
dence strongly suggests that aCL derived from APS patients 
that react to the complex of 32-GPI and CL in aCL ELISA 
(1, 5) recognize an epitope appearing on a conformationally 
altered/~2-GPI  structure resulting from interactions with an 
oxygenated solid phase surface. Our results also support a 
modal in which Bz-GPI binds to a surface containing anionic 
PLs (either micelles, liposomes, or biological membranes) and 
reveals an epitope(s) that is recognized by the aCL. 
Galli et al. (2), Arvicux et al. (18), and Viard et al. (19) 
have individually reported that aCL derived from autoim- 
mune patients (i.e., SLE and/or APS) were directed to the 
/~2-GPI molecule coated on polystyrene plates. However, we 
obtained no evidence that autoimmune aCL bound directly 
to the structure of 32-GPI either in the fluid phase or on 
plain polystyrene surfaces (solid phase). We have also noted 
that some commercially available plates  that are irradiated 
by the manufacturer, such as EB plates (Labsystems, Finland), 
Immnlon 2, and 4 (Dynatech, ChantiUy, VA), and Sumilon 
H  type  (Sumitomo Bakelite  Co.,  Ltd.),  showed /32-GPI 
binding of aCL in the absence of CL (our unpublished data). 
They did not state the surface conditions on the plates they 
had used. 
Hunt et al.  (28) reported that 32-GPI could be proteo- 
lyrically deaved between Lys-317 and Thr-318 (as a potential 
thrombin cleavage site) and the cleavage resulted in loosing 
lipid binding and activity to provide antibody binding in aCL 
ELISA. Thus, a neoepitope for aCL might be exposed on 
the region located near the COOH terminus (on the fifth 
sushi domain) of B2-GPI when Bz-GPI interacts with an ox- 
idized surface or anionic PLs. 
Finally, the definition of aCL specificity reinforces argu- 
ments that immune response could be addressed to lipid-bound 
32-GPI (and resulted in alteration of own structure) rather 
than lipid or ~2-GPI alone and that thrombotic complica- 
tions could be associated with Ba-GPI and aCL circulating 
in blood stream. 
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